Signaling through the M3 Muscarinic Receptor Favors Bone Mass Accrual by Decreasing Sympathetic Activity

Cell Metabolism

Volumn 11, Issue 3, 2010, Pages 231-238

  Shi, Yu ^a   Oury, Franck ^a   Yadav, Vijay K ^a   Wess, Jürgen ^b   Liu, X Sherry ^c   Guo, X Edward ^c   Murshed, Monzur ^d   Karsenty, Gerard ^a  

^a Columbia University ^*  (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c Division of Biomedical Sciences ^*  (United States)

^d Division of Endocrinology and Metabolism   (Canada)

Author keywords

HUMDISEASE

Indexed keywords

MUSCARINIC M3 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE REMODELING; CELL SPECIFICITY; CHOLINERGIC SYSTEM; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; MOUSE; MOUSE MUTANT; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYMPATHETIC TONE;

ANIMALS; BONE AND BONES; BONE RESORPTION; MICE; MICE, KNOCKOUT; NEURONS; OSTEOGENESIS; PARASYMPATHETIC NERVOUS SYSTEM; RECEPTOR, MUSCARINIC M3; SYMPATHETIC NERVOUS SYSTEM;

MUS;

EID: 77449109158     PISSN: 15504131     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmet.2010.01.005     Document Type: Article

References (34)

1. Agostoni E., Chinnock J.E., De Daly M.B., and Murray J.G. Functional and histological studies of the vagus nerve and its branches to the heart, lungs and abdominal viscera in the cat. J. Physiol. 135 (1957) 182-205
2. Brodal A. Neurological Anatomy in Relation to Clinical Medicine (1981), Oxford University Press, Oxford, UK
3. Buckley N.J., Bonner T.I., and Brann M.R. Localization of a family of muscarinic receptor mRNAs in rat brain. J. Neurosci. 8 (1988) 4646-4652
4. Caulfield M.P. Muscarinic receptors-characterization, coupling and function. Pharmacol. Ther. 58 (1993) 319-379
5. Caulfield M.P., and Birdsall N.J. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50 (1998) 279-290
6. Chruscinski A.J., Rohrer D.K., Schauble E., Desai K.H., Bernstein D., and Kobilka B.K. Targeted disruption of the beta2 adrenergic receptor gene. J. Biol. Chem. 274 (1999) 16694-16700
7. Cordell H.J. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum. Mol. Genet. 11 (2002) 2463-2468
8. Crawley J.N., Maas J.W., and Roth R.H. Evidence against specificity of electrical stimulation of the nucleus locus coeruleus in activating the sympathetic nervous system in the rat. Brain Res. 183 (1980) 301-311
9. Dacquin R., Starbuck M., Schinke T., and Karsenty G. Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev. Dyn. 224 (2002) 245-251
10. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., Shen J., Vinson C., Rueger J.M., and Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 (2000) 197-207
11. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., Kondo H., Richards W.G., Bannon T.W., Noda M., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434 (2005) 514-520
12. Eyre D.R., Dickson I.R., and Van Ness K. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem. J. 252 (1988) 495-500
13. Fu L., Patel M.S., Bradley A., Wagner E.F., and Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell 122 (2005) 803-815
14. Gautam D., Han S.J., Hamdan F.F., Jeon J., Li B., Li J.H., Cui Y., Mears D., Lu H., Deng C., et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab. 3 (2006) 449-461
15. Gautam D., Jeon J., Starost M.F., Han S.J., Hamdan F.F., Cui Y., Parlow A.F., Gavrilova O., Szalayova I., Mezey E., and Wess J. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proc. Natl. Acad. Sci. USA 106 (2009) 6398-6403
16. Goldstein D.S. The autonomic nervous system in health and disease (2001), Marcel Dekker, New York
17. Gomeza J., Shannon H., Kostenis E., Felder C., Zhang L., Brodkin J., Grinberg A., Sheng H., and Wess J. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. USA 96 (1999) 1692-1697
18. Gomeza J., Zhang L., Kostenis E., Felder C., Bymaster F., Brodkin J., Shannon H., Xia B., Deng C., and Wess J. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. USA 96 (1999) 10483-10488
19. Jetté L., Léger R., Thibaudeau K., Benquet C., Robitaille M., Pellerin I., Paradis V., van Wyk P., Pham K., and Bridon D.P. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 146 (2005) 3052-3058
20. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 4 (2006) 341-348
21. Kawai M., and Rosen C.J. Insulin-like growth factor-I and bone: lessons from mice and men. Pediatr. Nephrol. 24 (2008) 1277-1285
22. Matsui M., Motomura D., Karasawa H., Fujikawa T., Jiang J., Komiya Y., Takahashi S., and Taketo M.M. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc. Natl. Acad. Sci. USA 97 (2000) 9579-9584
23. Miyakawa T., Yamada M., Duttaroy A., and Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J. Neurosci. 21 (2001) 5239-5250
24. Rodan G.A., and Martin T.J. Therapeutic approaches to bone diseases. Science 289 (2000) 1508-1514
25. Shi Y., Yadav V.K., Suda N., Liu X.S., Guo X.E., Myers Jr. M.G., and Karsenty G. Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc. Natl. Acad. Sci. USA 105 (2008) 20529-20533
26. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., Armstrong D., Ducy P., and Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 111 (2002) 305-317
27. Tronche F., Kellendonk C., Kretz O., Gass P., Anlag K., Orban P.C., Bock R., Klein R., and Schütz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet. 23 (1999) 99-103
28. Weinstein R.S., Jilka R.L., Parfitt A.M., and Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102 (1998) 274-282
29. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit. Rev. Neurobiol. 10 (1996) 69-99
30. Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 423-450
31. Wess J., Eglen R.M., and Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 6 (2007) 721-733
32. Yadav V.K., Ryu J.H., Suda N., Tanaka K.F., Gingrich J.A., Schütz G., Glorieux F.H., Chiang C.Y., Zajac J.D., Insogna K.L., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135 (2008) 825-837
33. Yadav V.K., Oury F., Suda N., Liu Z.W., Gao X.B., Confavreux C., Klemenhagen K.C., Tanaka K.F., Gingrich J.A., Guo X.E., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138 (2009) 976-989
34. Yamada M., Miyakawa T., Duttaroy A., Yamanaka A., Moriguchi T., Makita R., Ogawa M., Chou C.J., Xia B., Crawley J.N., et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410 (2001) 207-212